Trial Profile
Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetic Patients With Coronary Artery Disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Vildagliptin/metformin (Primary) ; Metformin
- Indications Coronary artery disease; Type 2 diabetes mellitus
- Focus Biomarker; Pharmacodynamics
- Acronyms VAAST
- 18 Apr 2016 Status changed from recruiting to completed.
- 29 Jul 2013 Planned End Date changed from 1 Feb 2014 to 1 Feb 2015 as reported by ClinicalTrials.gov.
- 01 Sep 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.